Kelsi B. Holland

发表

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 2008, International journal of oncology.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.